<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9402">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05698563</url>
  </required_header>
  <id_info>
    <org_study_id>H-22033815</org_study_id>
    <nct_id>NCT05698563</nct_id>
  </id_info>
  <brief_title>Intermetatarsal Bursitis in Patients With Rheumatoid Arthritis</brief_title>
  <official_title>Clinical Implication of Intermetatarsal Bursitis in Patients With Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Danish Rheumatism Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to investigate the incidence and clinical implications of&#xD;
      intermetatarsal bursitis (IMB) in patients with rheumatoid arthritis (RA).&#xD;
&#xD;
      The hypothesis is that IMB is a cause of pain in patients with RA.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Within the recent years more research have focused on IMB in patients with rheumatologic&#xD;
      disorders. There is emerging evidence that IMB is an inflammatory alteration in line with&#xD;
      synovitis in patients with RA, and presence of IMB have been linked to the early stages of&#xD;
      RA, especially due to the focus of the published literature.&#xD;
&#xD;
      The clinical implications of the presence of IMB for the patients are yet to be understood.&#xD;
      Limited studies have linked the occurrence of IMB to foot impairment, but no studies have&#xD;
      been conducted investigating the direct association between forefoot pain and the&#xD;
      presence/absence of IMB.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 18, 2023</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a prospective diagnostic study, including a patient and a control group.&#xD;
There is a treatment option with standard treatment for the patient group, if there is indication based on the diagnostic imaging.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Outcome assessor is blinded to type of patient they are examining.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of intermetatarsal bursitis on MRI</measure>
    <time_frame>8 weeks</time_frame>
    <description>High intensity on T2 weighted images, low signal on T1. Thin peripheral enhancement on T1 contrast enhanced pictures.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of intermetatarsal bursitis on US</measure>
    <time_frame>8 weeks</time_frame>
    <description>Hypoechoic mass between metatarsal heads. Activity on power/color doppler.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of other pathology on MRI</measure>
    <time_frame>8 weeks</time_frame>
    <description>Other than intermetatarsal bursitis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of other pathology on US</measure>
    <time_frame>8 weeks</time_frame>
    <description>Other than intermetatarsal bursitis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Visual Analogue Score (VAS) score</measure>
    <time_frame>At inclusion, 1 and 3 month(s) post treatment</time_frame>
    <description>Pain score related to the foot pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of opening toes</measure>
    <time_frame>1 day</time_frame>
    <description>Presence of opening toes/V-sign/spreading toes.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Intermetatarsal Bursitis</condition>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Patient group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with rheumatoid arthritis and forefoot pain.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with other rheumatic diseases and absence of forefoot pain.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Magnetic resonance imaging</intervention_name>
    <description>MRI scan with contrast of the foot or feet</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Patient group</arm_group_label>
    <other_name>MRI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Ultrasound</intervention_name>
    <description>Ultrasound scan of the feet</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Patient group</arm_group_label>
    <other_name>US</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corticosteroid injection</intervention_name>
    <description>Administered ultrasound guided to patients with intermetatarsal bursitis</description>
    <arm_group_label>Patient group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clinical foot evaluation</intervention_name>
    <description>An examination of the feet</description>
    <arm_group_label>Patient group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Picture of the feet</intervention_name>
    <description>To evaluate the presence of V-sign/spreading toes</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Patient group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Forefoot pain and diagnosed with RA (patient group)&#xD;
&#xD;
          -  Diagnosed with an axial arthritis (control group)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18 years&#xD;
&#xD;
          -  Open wounds or ongoing infection in the forefoot at the time of examination&#xD;
&#xD;
          -  Persons with a history of significant trauma in the forefoot, e.g. any fracture or&#xD;
             previous surgeries in the forefoot&#xD;
&#xD;
          -  Persons who have previously received intermetatarsal treatment (Morton's neuroma or&#xD;
             IMB) in the same foot, e.g. injection within 6 months or operation at any time&#xD;
&#xD;
          -  Exclusion from MRI scan only:&#xD;
&#xD;
          -  Persons with contraindications to participate in MRI scan&#xD;
&#xD;
          -  Persons with severely impaired renal function (GFR &lt;30 ml/min)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sif B Larsen</last_name>
    <phone>+4521457551</phone>
    <email>sif.binder.larsen@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rigshospitalet Glostrup</name>
      <address>
        <city>Glostrup</city>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sif B Larsen, MD</last_name>
      <email>sif.binder.larsen@regionh.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>January 13, 2023</study_first_submitted>
  <study_first_submitted_qc>January 24, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2023</study_first_posted>
  <last_update_submitted>March 28, 2023</last_update_submitted>
  <last_update_submitted_qc>March 28, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Sif Binder Larsen</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Forefoot pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Bursitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

